Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer

Trial Details

NCT ID

NCT05346848

Phase

PHASE2

Sponsor

Institut Bergonié

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• Association of darolutamide and EBRT
• Association of ADT and EBRT

Locations (sample)

• Avignon, France|43.94834,4.80892
• Besançon, France|47.24878,6.01815
• Bordeaux, France|44.84124,-0.58046
• Brest, France|48.39029,-4.48628
• Marseille, France|43.29695,5.38107

Key Eligibility Criteria

• Histological diagnosis of prostate malignancy cancer
• Cancer without loco-regional or distant metastasis (tumor assessment must comprise at least Pelvic MRI AND thoraco-abdomino-pelvic contrast-enhance…
• Unfavorable intermediate risk prostate cancer diagnosis defined by the NCCN Guidelines.
• One of the following criteria is sufficient to define an unfavorable intermediate risk prostate cancer:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.